Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ohio State University Comprehensive Cancer Center
With
Pfizer
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Proven breast cancer
Metastatic or locally advanced breast cancer
Hormonally responsive disease defined as estrogen (ER) and/ or progesterone receptor (PR) positive (\>10% staining by immunohistochemistry)
Postmenopausal status
No more than 1 prior chemotherapy for stage IV metastatic breast cancer allowed
ECOG (Eastern Cooperative Oncology Group) performance status 0-2
Adequate organ function
You may not be if
No prior Exemestane or Fulvestrant
Uncontrolled intercurrent illness including but not limited to:
* ongoing or active infection
* symptomatic congestive heart failure
* unstable angina pectoris
* cardiac arrhythmia
* myocardial infarction within the last 3 months
* psychiatric illness/social situations that would limit compliance with study
Lymphangitic pulmonary disease; carcinomatous meningitis, bone marrow only metastases; and a rising tumor marker without any other site of metastatic disease.
Presence of bleeding diathesis or coagulopathy, patients requiring coumadin
Clareo Health | Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
